SUMMIT, N.J. (AP) — Biotechnology company Celgene Corp. said Tuesday its experimental psoriasis treatment, apremilast, met key goals in a midstage clinical trial. The company said apremilast reduced the severity of moderate-to-severe psoriasis during the study. Specifically, 41 percent of patients receiving the 30-milligram dose met treatment goals, compared with only 6 percent taking placebo. Psoriasis is a chronic inflammatory skin condition, with symptoms including redness and irritation. Celgene said results from the study support a move to advance the drug candidate to late-stage development in 2010.